1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Spain, MarketLine

Generics in Spain, MarketLine

  • January 2016
  • -
  • MarketLine
  • -
  • 32 pages

Introduction

Generics in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Spain generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The Spanish generics market is expected to generate total revenues of $3.5bn in 2015, representing a compound annual growth rate (CAGR) of 6.2% between 2011 and 2015.

- Market consumption volume is forecast to reach a total of 81.6% of total pharma volume in 2015.

- In Spain there is a great deal of difference in per capita public pharmaceutical expenditure. There is also a big difference in terms of prescriptions per capita. This is largely caused by differences in the age of its population in different areas. However, this gap is slowly closing. In 2014, the variation coefficient passed to 12.7% from 13.2% in 2013.

Features

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Spain

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Spain

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Spain generics market with five year forecasts by both value and volume

- Macroeconomic indicators provide insight into general trends within the Spain economy

Key Questions Answered

- What was the size of the Spain generics market by value in 2015?

- What will be the size of the Spain generics market in 2020?

- What factors are affecting the strength of competition in the Spain generics market?

- How has the market performed over the last five years?

- How large is Spain’s generics market in relation to its regional counterparts?

Table Of Contents

Generics in Spain, MarketLine
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Esteve Group 19
Mylan Inc. 20
Sandoz International GmbH 23
Teva Pharmaceutical Industries Limited 24
Macroeconomic Indicators 27
Country Data 27
Methodology 29
Industry associations 30
Related MarketLine research 30
Appendix 31
About MarketLine 31

List of Tables
Table 1: Spain generics market value: $ billion, 2011-15(e)
Table 2: Spain generics market volume: % of total pharma volume, 2011-15(e)
Table 3: Spain generics market geography segmentation: $ billion, 2015(e)
Table 4: Spain generics market value forecast: $ billion, 2015-20
Table 5: Spain generics market volume forecast: % of total pharma volume, 2015-20
Table 6: Esteve Group: key facts
Table 7: Mylan Inc.: key facts
Table 8: Mylan Inc.: key financials ($)
Table 9: Mylan Inc.: key financial ratios
Table 10: Sandoz International GmbH: key facts
Table 11: Teva Pharmaceutical Industries Limited: key facts
Table 12: Teva Pharmaceutical Industries Limited: key financials ($)
Table 13: Teva Pharmaceutical Industries Limited: key financial ratios
Table 14: Spain size of population (million), 2011-15
Table 15: Spain gdp (constant 2005 prices, $ billion), 2011-15
Table 16: Spain gdp (current prices, $ billion), 2011-15
Table 17: Spain inflation, 2011-15
Table 18: Spain consumer price index (absolute), 2011-15
Table 19: Spain exchange rate, 2011-15

List of Figures
Figure 1: Spain generics market value: $ billion, 2011-15(e)
Figure 2: Spain generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: Spain generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Spain generics market value forecast: $ billion, 2015-20
Figure 5: Spain generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the generics market in Spain, 2015
Figure 7: Drivers of buyer power in the generics market in Spain, 2015
Figure 8: Drivers of supplier power in the generics market in Spain, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Spain, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Spain, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Spain, 2015
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 15: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.